Vav3与恶性肿瘤的关系

doi:10.3760/cma.j.cn371439-20240215-00097

摘要/Abstract

摘要：

Vav鸟嘌呤核苷酸交换因子3（Vav3）蛋白是Rho家族GTP酶的鸟嘌呤核苷酸交换因子之一，由原癌基因Vav3编码，参与调节细胞的增殖、凋亡、分化以及迁移等。近年来，Vav3与多种恶性肿瘤的发展密切相关。在胶质瘤、乳腺癌、非小细胞肺癌、胃癌、胰腺癌、结直肠癌、前列腺癌、卵巢癌、骨肉瘤以及急性白血病中，Vav3的表达不同程度升高，并参与调控多个信号通路，促进肿瘤的进展，影响患者的预后。Vav3有望成为这些恶性肿瘤的潜在治疗靶点。

关键词: 肿瘤, Vav鸟嘌呤核苷酸交换因子3

Abstract:

Vav guanine nucleotide exchange factor 3 （Vav3） protein is one of the guanine nucleotide exchange factors of the Rho family GTPases. It is encoded by the proto-oncogene Vav3 and is involved in the regulation of cell proliferation and apoptosis， differentiation， migration， etc. In recent years， Vav3 has been closely related to the development of a variety of malignant tumors. In glioma， breast cancer， non-small cell lung cancer， gastric cancer， pancreatic cancer， colorectal cancer， prostate cancer， ovarian cancer， osteosarcoma and acute leukemia， the expression of Vav3 is elevated to varying degrees， and it participates in regulating multiple signaling pathways， which promotes the progression of tumors and affects the prognosis of patients. Therefore， Vav3 is expected to be a potential therapeutic target for these malignant tumors.

Key words: Neoplasms, Vav guanine nucleotide exchange factor 3

施学兵, 吴静, 邓文霞. Vav3与恶性肿瘤的关系[J]. 国际肿瘤学杂志, 2024, 51(9): 585-589.

Shi Xuebing, Wu Jing, Deng Wenxia. Relationship between Vav3 and malignant tumors[J]. Journal of International Oncology, 2024, 51(9): 585-589.

参考文献 35

[1]	Conde J, Fernández-Pisonero I, Cuadrado M, et al. Distinct roles of vav family members in adaptive and innate immune models of arthritis[J]. Biomedicines, 2021, 9(6): 695. DOI: 10.3390/biomedicines9060695.
[2]	Schäfer I, Bauch J, Wegrzyn D, et al. The guanine nucleotide exchange factor Vav3 intervenes in the migration pathway of oligodendrocyte precursor cells on tenascin-C[J]. Front Cell Dev Biol, 2022, 10: 1042403. DOI: 10.3389/fcell.2022.1042403.
[3]	Rodríguez-Fdez S, Lorenzo-Martín LF, Fabbiano S, et al. New functions of Vav family proteins in cardiovascular biology, skeletal muscle, and the nervous system[J]. Biology (Basel), 2021, 10(9): 857. DOI: 10.3390/biology10090857.
[4]	Ren W, Xu C, Wang S, et al. The effect of VAV3 polymorphisms on thyroid cancer[J]. Endocrine, 2022, 75(1): 178-184. DOI: 10.1007/s12020-021-02827-6.
[5]	Zhang Y, Zhang Y, Song Q, et al. The role of Vav3 expression for inflammation and cell death during experimental myocardial infarction[J]. Clinics (Sao Paulo), 2023, 78: 100273. DOI: 10.1016/j.clinsp.2023.100273.
[6]	Miao R, Huang D, Zhao K, et al. VAV3 regulates glioblastoma cell proliferation, migration, invasion and cancer stem‑like cell self‑ renewal[J]. Mol Med Rep, 2023, 27(4): 94. DOI: 10.3892/mmr.2023.12981.
[7]	Ojala VK, Knittle AM, Kirjalainen P, et al. The guanine nucleotide exchange factor VAV3 participates in ERBB4-mediated cancer cell migration[J]. J Biol Chem, 2020, 295(33): 11559-11571. DOI: 10.1074/jbc.RA119.010925. pmid: 32561640
[8]	Chen Z, Chen X, Lu B, et al. Up-regulated LINC01234 promotes non-small-cell lung cancer cell metastasis by activating VAV3 and repressing BTG2 expression[J]. J Hematol Oncol, 2020, 13(1): 7. DOI: 10.1186/s13045-019-0842-2.
[9]	Salhia B, Tran NL, Chan A, et al. The guanine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma[J]. Am J Pathol, 2008, 173(6): 1828-1838. DOI: 10.2353/ajpath.2008.080043. pmid: 19008376
[10]	Løyland B, Sandbekken IH, Grov EK, et al. Causes and risk factors of breast cancer, what do we know for sure? An evidence synthesis of systematic reviews and meta-analyses[J]. Cancers (Basel), 2024, 16(8): 1583. DOI: 10.3390/cancers16081583.
[11]	Zuo Q, Park NH, Lee JK, et al. Liver metastatic breast cancer: epidemiology, dietary interventions, and related metabolism[J]. Nutrients, 2022, 14(12): 2376. DOI: 10.3390/nu14122376.
[12]	Guvakova MA. Automated classification of breast cancer across the spectrum of ERBB2 expression focusing on heterogeneous tumors with low human epidermal growth factor receptor 2 expression[J]. JCO Clin Cancer Inform, 2023, 7: e2300013. DOI: 10.1200/CCI.23.00013.
[13]	Chen X, Chen SI, Liu XA, et al. Vav3 oncogene is upregulated and a poor prognostic factor in breast cancer patients[J]. Oncol Lett, 2015, 9(5): 2143-2148. DOI: 10.3892/ol.2015.3004. pmid: 26137028
[14]	Lu DC, Han W, Lu K. Identification of key microRNAs involved in tumorigenesis and prognostic microRNAs in breast cancer[J]. Math Biosci Eng, 2020, 17(4): 2923-2935. DOI: 10.3934/mbe.2020164. pmid: 32987507
[15]	Yin Z, Guo X, Liang X, et al. FTO promotes gastric cancer progression by modulating MAP4K4 expression via demethylation in an m6A-dependent manner[J]. Med Oncol, 2024, 41(5): 120. DOI: 10.1007/s12032-024-02369-7.
[16]	Tan B, Li Y, Shi X, et al. Expression of Vav3 protein and its prognostic value in patients with gastric cancer[J]. Pathol Res Pract, 2017, 213(5): 435-440. DOI: 10.1016/j.prp.2017.01.028. pmid: 28285969
[17]	Xu Y, Yu X, Xu J, et al. LncRNA RP11-138J23.1 contributes to gastric cancer progression by interacting with RNA-binding protein HuR[J]. Front Oncol, 2022, 12: 848406. DOI: 10.3389/fonc.2022.848406.
[18]	Ma RR, Zhang H, Chen HF, et al. MiR-19a/miR-96-mediated low expression of KIF26A suppresses metastasis by regulating FAK pathway in gastric cancer[J]. Oncogene, 2021, 40(14): 2524-2538. DOI: 10.1038/s41388-020-01610-7.
[19]	Tsuboi M, Taniuchi K, Furihata M, et al. Vav3 is linked to poor prognosis of pancreatic cancers and promotes the motility and invasiveness of pancreatic cancer cells[J]. Pancreatology, 2016, 16(5): 905-916. DOI: 10.1016/j.pan.2016.07.002. pmid: 27453460
[20]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[21]	Uen YH, Fang CL, Hseu YC, et al. VAV3 oncogene expression in colorectal cancer: clinical aspects and functional characterization[J]. Sci Rep, 2015, 5: 9360. DOI: 10.1038/srep09360.
[22]	Liao R, Ma QZ, Zhou CY, et al. Identification of biomarkers related to tumor-infiltrating lymphocytes (TILs) infiltration with gene co-expression network in colorectal cancer[J]. Bioengineered, 2021, 12(1): 1676-1688. DOI: 10.1080/21655979.2021.1921551. pmid: 33960283
[23]	Zhang X, Wan S, Yu Y, et al. Identifying potential DNA methylation markers in early-stage colorectal cancer[J]. Genomics, 2020, 112(5): 3365-3373. DOI: 10.1016/j.ygeno.2020.06.007. pmid: 32531444
[24]	Zhang Y, Wu Q, Xu L, et al. Sensitive detection of colorectal cancer in peripheral blood by a novel methylation assay[J]. Clin Epigenetics, 2021, 13(1): 90. DOI: 10.1186/s13148-021-01076-8.
[25]	Chen H, Pang B, Zhou C, et al. Prostate cancer-derived small extracellular vesicle proteins: the hope in diagnosis, prognosis, and therapeutics[J]. J Nanobiotechnology, 2023, 21(1): 480. DOI: 10.1186/s12951-023-02219-0.
[26]	Lin KT, Gong J, Li CF, et al. Vav3-rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence[J]. Cancer Res, 2012, 72(12): 3000-3009. DOI: 10.1158/0008-5472.CAN-11-2502.
[27]	Aboukameel A, Muqbil I, Baloglu E, et al. Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression[J]. Oncotarget, 2018, 9(82): 35327-35342. DOI: 10.18632/oncotarget.26239. pmid: 30450161
[28]	Zhao N, Peacock SO, Lo CH, et al. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer[J]. Sci Transl Med, 2019, 11(498): eaaw4636. DOI: 10.1126/scitranslmed.aaw4636.
[29]	Giles KA, Gould CM, Achinger-Kawecka J, et al. BRG1 knockdown inhibits proliferation through multiple cellular pathways in prostate cancer[J]. Clin Epigenetics, 2021, 13(1): 37. DOI: 10.1186/s13148-021-01023-7.
[30]	Jing L, Hua X, Yuanna D, et al. Exosomal miR-499a-5p inhibits endometrial cancer growth and metastasis via targeting VAV3[J]. Cancer Manag Res, 2020, 12: 13541-13552. DOI: 10.2147/CMAR.S283747. pmid: 33408524
[31]	Reimer D, Boesch M, Wolf D, et al. Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response[J]. Int J Cancer, 2018, 142(8): 1640-1651. DOI: 10.1002/ijc.31186. pmid: 29194596
[32]	Xiao Y, Li C, Wang H, et al. LINC00265 targets miR-382-5p to regulate SAT1, VAV3 and angiogenesis in osteosarcoma[J]. Aging (Albany NY), 2020, 12(20): 20212-20225. DOI: 10.18632/aging.103762.
[33]	Mu D, Long S, Guo L, et al. High expression of VAV gene family predicts poor prognosis of acute myeloid leukemia[J]. Technol Cancer Res Treat, 2021, 20: 15330338211065877. DOI: 10.1177/15330338211065877.
[34]	Hegde S, Gasilina A, Wunderlich M, et al. Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia[J]. Leukemia, 2022, 36(3): 637-647. DOI: 10.1038/s41375-021-01455-3.
[35]	Nayak RC, Chang KH, Singh AK, et al. Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis[J]. Nat Commun, 2022, 13(1): 3056. DOI: 10.1038/s41467-022-30651-7.